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Background: Malaria is an endemic disease affecting many countries in Tropical regions. In the search for
compound hits for the design and/or development of new drugs against the disease, many research teams have
resorted to African medicinal plants in order to identify lead compounds. Three-dimensional molecular models were
generated for anti-malarial compounds of African origin (from ‘weakly’ active to ‘highly’ active), which were
identified from literature sources. Selected computed molecular descriptors related to absorption, distribution,
metabolism, excretion and toxicity (ADMET) of the phytochemicals have been analysed and compared with those
of known drugs in order to access the ‘drug-likeness’ of these compounds.
Results: In the present study, more than 500 anti-malarial compounds identified from 131 distinct medicinal plant
species belonging to 44 plant families from the African flora have been considered. On the basis of Lipinski’s ‘Rule
of Five’ , about 70% of the compounds were predicted to be orally bioavailable, while on the basis of Jorgensen’s
‘Rule of Three’ , a corresponding >80% were compliant. An overall drug-likeness parameter indicated that
approximately 55% of the compounds could be potential leads for the development of drugs.
Conclusions: From the above analyses, it could be estimated that >50% of the compounds exhibiting anti-plasmodial/
anti-malarial activities, derived from the African flora, could be starting points for drug discovery against malaria.
The 3D models of the compounds have been included as an accompanying file and could be employed in virtual
screening.
Keywords: Africa; Malaria; Medicinal plants; Metabolism; Natural products; PharmacokineticsBackground
Malaria is an endemic disease which affects vast propor-
tions of the populations of most Tropical countries (cov-
ering Africa, Asia and Latin America) [1,2]. The disease
condition is caused by protozoans of the Plasmodium
genus, mostly Plasmodium falciparum [3]. Statistics show
that about half of the world’s population is at risk of
contracting malaria and that 1 to 2 million annual deaths
(mostly amongst African children) can be attributed to* Correspondence: lmbazze@yahoo.fr
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in any medium, provided the original work is pmalaria alone [2-4]. In addition, the spread of the disease
has been enhanced by the development of resistance in
the anopheline vector against standard insecticides,
amongst other factors, which have not unfortunately
been put under check [5].
One promising way to fight malaria is to search for
vaccines and new drugs, since no vaccine has yet been put
in the market and the disease-causing parasites have de-
veloped resistant strains against existing chemotherapies
[5-7]. It should however be mentioned that the process of
discovering a drug is quite timely and costly [8]. One of
the current approaches for shortening the time required
and cutting down the cost for the discovery of leadis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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drug targets is to incorporate computer-based methods
like docking techniques, pharmacophore-based searches
and neural networking [9-13]. Computer-based methods
have also been incorporated in the prediction of likely
metabolic pathways of drug molecules, as well as predict
their pharmacokinetic profiles [14-17]. The absorption,
distribution, metabolism, excretion and toxicity (ADMET)
profile of a potential drug molecule should be known if it
has to stand the chances of entering the market. Hence,
assessing such information for lead compounds early
enough would help eliminate molecules with predicted
uninteresting profiles and eventually cut down the price
of drug discovery [8].
With the accumulation of ‘wet lab’ biodata on drug
metabolism and pharmacokinetics (DMPK) by the close
of the 1990s, pharmaceutical companies are increasingly
switching over to the use of statistical and knowledge-
based methods, implemented in computer software, in
the prediction of ADMET/DMPK properties of drug
leads, in contrast to the former approach which is more
costly and time consuming [14-17]. In our quest to as-
sess the potential of natural products (NPs) derived from
African medicinal plants for the development of anti-
malarial drugs [18,19], an in silico approach based on
computed molecular descriptors has been carried out, in
comparison with those of known drugs, as previously de-
scribed in the literature [20-24]. In this paper, we present
a computer-based DMPK analysis of >500 anti-malarial
compounds, which have been previously isolated from
the African flora.Methods
Data sources
The plant sources, geographical collection sites, chemical
structures of pure compounds as well as their spectro-
scopic data were retrieved from literature sources com-
prising of MSc theses, PhD theses, textbook chapters
and journal articles, with references ranging from 1971
to 2013. A full list of journals consulted is given in the
supplementary material (Additional file 1). By conven-
tion, activities were categorized into ‘very potent’, ‘good’,
‘good to moderate’, ‘weak’, ‘very weak’ and ‘inactive’. Fol-
lowing the criteria used by Mahmoudi et al. [25] and
Wilcox et al. [26], a pure compound was considered
highly active if IC50 < 0.06 μM, being active with
0.06 μM ≤ IC50 ≤ 5 μM, weakly active when 5 μM ≤
IC50 ≤ 10 μM, and compounds with IC50 > 10 μM were
considered inactive. The following inhibition percent-
ages were proposed for in vivo activity of anti-malarial
extracts at a fixed dose of 250 mg kg−1 day−1: 100% to
90% (very good activity), 90% to 50% (good to moderate),
50% to 10% (moderate to weak) and 0% (inactive) [27].Generation of 3D models, optimization and correction of
protonation states
The 2D structures of the compounds were retrieved
from the literature sources, and all 3D molecular models
were generated using the graphical user interface (GUI)
of the MOE software [28] running on a Linux worksta-
tion with a 3.5 GHz Intel Core2 Duo processor. The 3D
structures were generated using the builder module of
MOE, and energy minimization was subsequently car-
ried out using the MMFF94 force field [29] until a gradi-
ent of 0.01 kcal mol−1 was reached. The 3D structures of
the compounds were then saved as .mol2 files subse-
quently treated with LigPrep [30]. This implementation
was carried out with the GUI of the Maestro software
package [31], using the optimized potentials for liquid
simulations (OPLS) forcefield [32-34]. Protonation states
at biologically relevant pH were correctly assigned
(group I metals in simple salts were disconnected, strong
acids were deprotonated, strong bases protonated, while
topological duplicates and explicit hydrogens were added).
The generated 3D models have been included in the
supplementary material (Additional file 2).
Calculation of molecular descriptors
A set of ADMET-related properties (a total of 46
molecular descriptors) were calculated by using the
QikProp program [35] running in normal mode. QikProp
generates physically relevant descriptors and uses them
to perform ADMET predictions. An overall ADME-
compliance score - drug-likeness parameter (indicated
by #stars) - was used to assess the pharmacokinetic
profiles of the compounds. The #stars parameter indi-
cates the number of property descriptors computed by
QikProp that fall outside the optimum range of values
for 95% of known drugs. The methods implemented
were developed by Jorgensen and Duffy [36-38]. Some
of the computed ADMET descriptors are shown in
Additional file 3: Table S1, along with their significance
in DMPK profiling and the recommended ranges for
95% of known drugs.
Results and discussion
Plant families and compound types
From this survey, 511 anti-malarial compounds were
identified from 131 plant species belonging to 45 fam-
ilies, a majority being isolated from the Loganiaceae
family (10.6%). Significant proportions were also iden-
tified from the Guttiferae, Zingiberaceae, Rutaceae,
Asteraceae, Ancistrocladaceae, Annonaceae, Clusiaceae,
Meliaceae, Sapindaceae, Lamiaceae, Moraceae, Dionco-
phyllaceae, Cyperaceae, Asphodelaceae, Leguminosae,
Periplocaceae and Bignoniaceae families, with respect-
ive percentage compound counts of 8.0%, 7.1%, 6.9%,
6.4%, 4.3%, 4.0%, 3.6%, 3.6%, 3.6%, 3.5%, 3.5%, 2.8%,
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malarials (Figure 1). Less than 2% of the anti-malarials
were isolated from each of the remaining plant families.
A majority of the compounds were terpenoids (30.7%),
followed by alkaloids, flavonoids, quinones and xanthones,
respectively representing 27.7%, 12.9%, 4.5% and 4.5% by
compound count (Figure 2). Only 20 compounds were
identified with in vivo anti-malarial activities, while 278
compounds showed in vitro activities from moderate to
very high activities. These have been discussed in our pre-
vious review articles in this series [18,19].Significance of selected computed molecular descriptors
Selected molecular descriptors, along with the recom-
mended range of values for 95% of known drugs, as
computed by the QikProp program [35], have been
shown in Additional file 3: Table S1. According to
Lipinski’s ‘Rule of Five’, a compound is likely to be orally
available when the molecular weight (MW) <500, the
logarithm of the octan-1-ol/water partition coefficient
(log P) < 5, the number of hydrogen donors (HBD) ≤5
and the number of hydrogen bond acceptors (HBA) ≤10
[39]. Compounds which comply with this rule are con-
sidered to be drug-like. Moreover, Jorgensen’s ‘Rule of
Three’ has often been used as a criterion to predict oral
availability of drugs [40]. According to this rule, a com-
pound will more likely be orally available when all or
some of the rules, the logarithm of the predicted aque-
ous solubility (log Swat) > −5.7, the predicted Caco-2
permeability (BIPCaco − 2) >22 nm s
−1 and the number
of primary metabolites <7, are respected. The solubility
calculation procedure implemented depends on the
similarity property space between the given moleculeFigure 1 Bar chart showing the distribution of the 511 anti-malarial cand its most similar analogue within the experimental
training set used to develop the model implemented in
QikProp; i.e., if the similarity is <0.9, then the QikProp
predicted value is taken, otherwise, the predicted prop-
erty, Ppred, is adjusted such that
Ppred ¼ SPexp þ 1−Sð ÞPQP ð1Þ
where S is the similarity, and Pexp and PQP are the respect-
ive experimental and QikProp predictions for the most
similar molecule within the training set. In Equation 1, if
S = 1, then the predicted property is equal to the measured
experimental property of the training set compound. The
predicted apparent Caco-2 cell permeability, BIPCaco − 2
(in nm s−1), models the permeability of the gut-blood
barrier (for non-active transport), even though this param-
eter is not often correctly predicted computationally [41].
Moreover, a molecule’s size, its capacity to make hydrogen
bonds, its overall lipophilicity, and its shape and flexibility
are important properties to consider when determining
permeability. Molecular flexibility has been seen as a par-
ameter which is dependent on the number of rotatable
bonds (NRB), a property which influences bioavailability
in rats [42].
The overall drug-likeness of a molecule is often deter-
mined by the #stars parameter, which depends on 24
computed parameters (descriptors) of a molecule with
respect to the recommended range for 95% of known
drugs (Additional file 3: Table S1). A #star = 0 corre-
sponds to an ideally drug-like molecule, while #stars = n
indicates that a given molecule has n non-compliant de-
scriptors (values fall outside the recommended range for
95% of known drugs). The solubility of a drug, evaluated
by the model of Jorgensen and Duffy [36,37], determinesompounds by plant family of origin.
Figure 2 Pie chart showing the classification by compound types.
Table 1 Minimum, maximum and mean values for
computed Lipinski parameters
Lipinski parameter Minimum Mean Maximum
MW (Da) 78.1 394.1 1084.7
log P −5.1 3.2 16
HBA 0 6.4 28
HBD 0 1.8 17
NRB 0 5.9 32
LV 0 0.5 3
LV, Lipinski violations.
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availability of a compound depends on the processes of
absorption and liver first-pass metabolism [43]. Absorp-
tion in turn depends on the solubility and permeability
of the compound, as well as interactions with trans-
porters and metabolizing enzymes in the gut wall.
The computed blood/brain partition coefficients (log
B/B) of drug molecules are often used as indicators to
predict access to the central nervous system (CNS). This
is because too polar drugs do not cross the blood/brain
barrier (BBB). In addition, Madin-Darby canine kidney
(MDCK) monolayers are widely used to make oral ab-
sorption estimates, the reason being that these cells also
express transporter proteins but only express very low
levels of metabolizing enzymes [42]. They are also used
as an additional criterion to predict BBB penetration.
Thus, our calculated apparent MDCK cell permeability
could be considered to be a good mimic for the BBB (for
non-active transport). The predicted skin permeability
parameter (log Kp) is another important parameter for
drug distribution [44,45]. The predicted maximum trans-
dermal transport rates, Jm (in μ cm
−2 h−1), were computed
from the aqueous solubility (Swat) and skin permeability
(Kp), using the relation (2), also expresses the efficiency of
drug distribution:
Jm ¼ Kp MW  Swat ð2Þ
The efficiency and distribution of a drug may be af-
fected by the degree to which it binds to the proteins
within blood plasma. When a drug binds to plasma pro-
teins (like human serum albumin, lipoprotein, glycopro-
tein, α, β‚ and γ globulins), the quantity of the drug in
general blood circulation is greatly reduced and hence
the less bound a drug is, the more efficiently it can
traverse cell membranes. The predicted plasma-protein
binding has been estimated by the prediction of bindingto human serum albumin; the log KHSA parameter (rec-
ommended range is −1.5 to 1.5 for 95% of known drugs).
The number of metabolic steps (#metab) also deter-
mines whether the molecules can easily gain access to
the target site after entering the blood stream.
The toxicity parameter is often predicted by the loga-
rithm of IC50 values for blockage of the human ether-a-
go-go related gene (HERG). HERG encodes a potassium
ion (K+) channel that is implicated in the fatal arrhythmia
known as torsade de pointes or the long QT syndrome
[46]. The HERG K+ channel is best known for its contri-
bution to the electrical activity of the heart that coordi-
nates the heart’s beating. It therefore appears to be the
molecular target responsible for the cardiac toxicity of a
wide range of therapeutic drugs [47]. HERG has also been
associated with modulating the functions of some cells of
the nervous system and with establishing and maintaining
cancer-like features in leukemic cells [48]. Thus, HERG
K+ channel blockers are potentially toxic and the pre-
dicted IC50 values often provide reasonable predictions
for cardiac toxicity of drugs in the early stages of drug
discovery [49].
Lipinski’s criteria for evaluation of oral bioavailability
Lipinski’s ‘rule’ was extracted from chemical libraries
from the World Dug Index (WDI) as a criterion to
evaluate likely oral bioavailability [39,50]. This rule did
not take NPs into consideration initially, since Lipinski
had postulated that the Rule of Five was not respected
by NPs. However, NP libraries have been previously ana-
lysed comparatively using this rule in order to have a
rough idea of the extent of ‘drug-likeness’ of a compound
library to be used in virtual screening [20-22,51,52]. In
summary, 352 of the 511 compounds analysed showed
no violations of Lipinski rules, while 435 compounds
showed <2 violations. The maximum number of viola-
tions was 3 and the average number was 0.5 (Table 1).
This implies that the anti-malarial compounds from the
African flora could generally be categorized as ‘drug-
like’ up to approximately 70%. Considering the individ-
ual parameters, it was observed that for the MW, 432
out of the 511 compounds analysed complied with
Figure 3 Graph distribution of Lipinski determinant of ‘drug-likeness’. (A) Bar chart showing distribution of MW. (B, C, D and E) Distribution
curves of the log P, HBA, HBD and NRB respectively for the 511 anti-malarial compounds from the African flora. (F) Scatter plot of MW against
log P. For (B), the x-axis label is the lower limit of binned data, e.g., 0 is equivalent to 0.00 to 0.99.
Table 2 Mean values and percentage compliances of
selected ADMET-related descriptors for 511 anti-malarial
compounds from African medicinal plants
Propertya Mean value Percentage compliance









log Swat (S in mol L
−1) −4.3 79.3






log Kp −3.2 93.3
#metab 5.4 84.5
aThe descriptors (entries in the first column and the recommended ranges for
95% of drugs) are defined in Additional file 3: Table S1.
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Meanwhile, the greatest proportion of the molecules
had MW in the interval 301 ≤MW ≤ 400, Figure 3A.
The log P curve showed a Gaussian-shape, centred on a
peak value of 1.5 log P units, with approximately 88%
of the compounds complying to Lipinski’s criterion
(log P < 5), Figure 3B. The graphs of the HBA, HBD
and NRB have been shown in Figure 3C,D,E. The num-
ber of HBA rose rapidly to a peak value of 4 acceptors,
comprising 102 compounds, then fell off rapidly to 28
acceptors for the most complex NPs in this study. The
curve for the HBD had a maximum at 0 donors (for
149 of the compounds) and fell off to 1 compound
having as many as 17 donors. The distribution for the
NRB gave a rugged curve with a peak value at 4 ro-
tatable bonds (RBs), comprising 68 compounds and
as many as 32 RBs for the most flexible compound. A
scatter plot of MW against log P showed that the re-
gion of maximum density of points lay in the interval
MW ≤ 500 ∩ log P ≤ 5, defined as Lipinski’s compli-
ance region (LCR). A similar trend was seen in the
pairwise scatter plots of the other parameters (results
not shown).
Jorgensen’s criteria for assessment of oral bioavailability
In the assessment of oral bioavailability, 279 com-
pounds showed no violation of the Rule of Three, while
422 compounds violated this rule only once, indicating
that >80% of the compounds are predicted to be orally
bioavailable. Regarding the individual parameters, the
solubility parameter showed a significant performance,
with about 80% of the compounds complying with therecommended range for 95% of known drugs (−6 ≤ log
Swat ≤ 0.5). In accordance to Jorgensen’s ro3, 77.3% of
the compounds had log Swat > 5.7, while 91% complied
with the BIPCaco − 2 > 22 nm s
−1 criterion. The percentage
of compounds complying with each of the other DMPK
parameters has been shown in Table 2. The distribution
curves of both parameters are shown in Figure 4A,B,
along with the histogram for the human oral absorption
(HOA) parameter. It was estimated that 312 compounds
Figure 4 Distribution of parameters for oral bioavailability and human oral absorption. (A) log Swat, (B) BIPCaco-2 and (C) HOA. For the
HOA parameter (C), 1, low absorption; 2, medium absorption; 3, high absorption.
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Figure 4C), while 64 compounds were estimated to
have medium HOA (attributed to a value of 2) and 135
compounds were estimated to have low absorption. Es-
timations of the percentage of human oral absorption
(PHOA) showed that 38.1% of the compounds could
be absorbed at 100%, while 52.2% could be absorbed
at >90% and 69.9% were estimated to have high PHOA
(i.e., absorbed at >80%).Assessment of the overall DMPK compliance by the
drug-likeness parameter
The #stars parameter was also used to evaluate the over-
all drug-likeness of the anti-malarial compounds from
African flora. The distribution curve for this parameter
has been shown in Figure 5. The graph started with 0
violations of drug-likeness indicators (corresponding to
a maximum number of 282 compounds) and went up
to 15 violations. The steepness of the curve, however,
showed that the compounds had an overall interesting
drug-likeness. Additionally, 79.2% of the compounds vi-
olated only ≤2 out of the recommended range of values
for the 24 essential descriptors of drug-likeness com-
puted by QikProp in this study.Figure 5 Distribution curves for #stars for 511 anti-malarial compounPrediction of drug distribution and binding to human
serum albumin and dermal penetration parameters
The distribution of the compounds was simulated by
calculation of binding affinities to human serum albumin
(HSA). The distribution of log KHSA gave a smooth
Gaussian-shaped curve with a peak value at 0.5 log KHSA
units (Figure 6A), with 83.6% of the compounds falling
within the required range for 95% of drugs. This is an in-
dication that a significant proportion of the compounds
are likely to circulate freely in the blood stream and hence
reach the drug target sites.
The skin permeability parameter showed 93.3% com-
pliance with 95% of drugs. The distribution curve was a
Gaussian-shape centred on −2.5 log Kp units (Additional
file 3: Figure S1), while the predicted maximum transder-
mal transport rates, Jm (in μ cm
−2 h−1), were estimated to
vary from 0 to about 1,640 units, with only five compounds
having predicted value of Jm > 100 μ cm
−2 h−1.Prediction of blood/brain barrier penetration and activity
in the central nervous system
Access to the central nervous system was simulated by the
log B/B parameter, while activity in the central nervous
system was estimated by the CNS parameter (on the −2 =ds derived from African medicinal plants.
Figure 6 Plot of the physicochemical descriptors used to predict DMPK. (A) Predicted log KHSA against count, (B) Predicted log B/B against
count and (C) Predicted # metab against count.
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showed a sharp peak at 0.5 log B/B units, with 93.3% com-
pliance with 95% of drugs. On the other hand, only 3.5%
of the compounds were estimated to have an activity in
the central nervous system.Prediction of number of likely metabolic reactions
The number of likely metabolic steps was also computed
by QikProp and plotted against the counts (Figure 6C).
This parameter is often used to assess the likelihood of a
molecule to easily gain access to the target site after en-
tering the blood stream. The average estimated number
of possible metabolic reactions was between 5 and 6,
even though some of the compounds are likely to
undergo as many as up to 16 metabolic reactions due to
the complexity of some of the plant secondary metabo-
lites. About 84% of the compounds are predicted to
undergo the recommended number of metabolic steps
(1 to 8 reactions),
Prediction of toxicity by blockage of HERG K+ channel
In this study, the estimated or predicted IC50 values for
blockage of the HERG K+ channel have been used toFigure 7 A plot of predicted logHERG values for 511 anti-malarial compmodel the drug toxicity in silico. The recommended
range for predicted log IC50 values for blockage of
HERG K+ channels (logHERG) is > −5. A distribution
curve for the variation of the predicted logHERG is
shown in Figure 7, which is a left-slanted Gaussian-
shaped curve, with a peak at −5.5 logHERG units. It was
observed that in general, this parameter is predicted to
fall within the recommended range for about 57% of the
compounds.Conclusions
In this study, the calculated physicochemical properties
and indicators of drug-likeness have been used in the as-
sessment of the ADMET/DMPK profiles of >500 com-
pounds isolated from medicinal plants in Africa, which
have exhibited from weak to high in vitro and/or in vivo
anti-plasmodial/anti-malarial activity. The overall esti-
mate gave good compliance with the computed parame-
ters for 95% of known drugs, as well as with Lipinski’
drug-likeness criteria. The results give good reason for
further investigation of the suitability of anti-malarial
compounds derived from African flora to be directly
employed as drugs or as lead compounds from whichounds derived from the African flora.
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ated 3D structures of the compounds have been in-
cluded as a supplementary file (Additional file 2), while
enquiries for the availability of compounds for screening
purposes could be addressed to the p-ANAPL consor-
tium [52], which has the mandate to collect compound
samples from African flora for biological screening
purposes.
Additional files
Additional file 1: List of journals consulted in the literature search.
Additional file 2: The 3D structures of the anti-malarial compounds
isolated from African medicinal plants in this survey. This file is saved
in .sdf format (which can be viewed using a wide range of software,
including MOE, LigandScout, Discovery Studio, and Maestro).
Additional file 3: Table S1. Selected computed ADMET-related
descriptors and their recommended ranges for 95% of known drugs.
Figure S1. Distribution curves for the predicted skin permeability
parameter.
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